Want to see AU:AN1 full AI Analyst Report?
AN1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins in the ~40–64% range provide a durable profit buffer for the core product portfolio. That margin profile supports investments in marketing, distribution and R&D while giving a clearer route to operating leverage if revenue stabilises or returns to growth.
Established Consumer Brand And ChannelsA recognizable branded offering and multi-channel retail/distribution presence are durable assets in consumer health. Brand equity and existing shelf/distribution relationships support repeat purchase, extension opportunities and more efficient customer acquisition versus a nascent competitor.
Improving Loss And Cash-burn TrendA materially smaller loss year-over-year and reduced cash burn reflect tangible operating progress. If sustained, this trend lowers near-term funding pressure and indicates the business is moving closer to break-even, improving the chance that operational fixes are having durable effect.
Bears Say
Persistent Operating LossesRecurring negative profitability means the core operations are not yet self-sustaining. Continued operating losses erode shareholder equity, constrain reinvestment capacity, and maintain reliance on external funding until the company consistently reaches operating break-even.
Consistent Negative Cash GenerationPersistent negative operating and free cash flow indicate the business is not self-funding and must rely on financing or equity to operate. This raises structural liquidity and execution risk, limiting flexibility to invest in growth or absorb demand shocks without dilutive or costly capital raises.
Sharp Revenue Decline And Equity ErosionA steep revenue contraction plus materially reduced equity undermine scale economics and the balance-sheet cushion. Weaker top-line momentum hampers prospects for margin recovery and increases vulnerability to funding issues, making sustained turnaround more challenging.
Anagenics News
AN1 FAQ
What was Anagenics Limited’s price range in the past 12 months?
Currently, no data Available
What is Anagenics Limited’s market cap?
Anagenics Limited’s market cap is AU$5.91M.
When is Anagenics Limited’s upcoming earnings report date?
Anagenics Limited’s upcoming earnings report date is Sep 02, 2026 which is in 17 days.
How were Anagenics Limited’s earnings last quarter?
Anagenics Limited released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Anagenics Limited overvalued?
According to Wall Street analysts Anagenics Limited’s price is currently Overvalued.
Does Anagenics Limited pay dividends?
Anagenics Limited does not currently pay dividends.
What is Anagenics Limited’s EPS estimate?
Anagenics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anagenics Limited have?
Anagenics Limited has 985,450,800 shares outstanding.
What happened to Anagenics Limited’s price movement after its last earnings report?
Anagenics Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Anagenics Limited?
Currently, no hedge funds are holding shares in AU:AN1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anagenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.93%
Trailing 12-Months
Company Description
Anagenics Limited
Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
EVE Health Group Limited
―
Skin Elements Limited
―
Holista Colltech Limited
―
Nutritional Growth Solutions Ltd.
―
Hydration Pharmaceuticals Co. Ltd.
―